RepliCel Life Sciences, a regenerative medicine company and maker of autologous cell therapies RCS-01 for skin rejuvenation and RCH-01 for hair restoration and proprietary injection device, RCI-02, has announced the election and appointment of its incoming Board of Directors.
The re-elected directors are David Hall (chair), Peter Lowry, Andrew Schutte, Peter Lewis, Larissa Huang and Lee Buckler. The board also increased its members from six to seven and elected Zhan (Gavin) Ye to join the returning members. Ye has a Bachelor’s of Science from the Technical University of Delft (The Netherlands) and a Bachelor’s of Science for the University of Victoria (Canada). His background is in the financial services sector, the commodity exchange industry and, most recently, in international product development and brand building driven by deep data analytics.
“As RepliCel expands the development of its products internationally with a particular focus on Asia, we anticipate Mr. Ye will be a valuable addition to RepliCel’s Board of Directors,” said Hall. “Gavin has deep cross-border experience between Canada and Hong Kong, China, Singapore, South Korea, and Taiwan, which we anticipate will play an instrumental role in RepliCel’s business activities in Asia both with our existing partners and new partnerships being explored.”
